Literature DB >> 13067022

Urinary tract infections; problems in medical management.

E JAWETZ.   

Abstract

The lesion principally responsible for chronic, or recurrent, urinary tract infection is a focus in the interstitial tissue of the kidney. Most cursory antimicrobial therapy suppresses the manifestations of lower urinary tract involvement but does not eradicate the renal focus. In order to cure rather than merely suppress the infection, it is imperative that, as early as possible, steps be taken to isolate and identify the etiologic microorganism and to determine its sensitivity to antimicrobial agents. Based on this information sufficient amounts of drug should be given for an adequate period (probably at least two weeks) to eradicate the infection within the renal tissue. Such a program would tend to reduce the number of cases in which irreversible renal failure develops from chronic pyelonephritis.

Entities:  

Keywords:  PYELONEPHRITIS/therapy; URINARY TRACT/diseases

Mesh:

Year:  1953        PMID: 13067022      PMCID: PMC1522012     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  8 in total

1.  The responsibility of an internist in the treatment of pyelonephritis.

Authors:  R BIRCHALL
Journal:  J Urol       Date:  1952-11       Impact factor: 7.450

2.  Polymyxin B in chronic pyelonephritis: observations on the safety of the drug and on its influence on the renal infection.

Authors:  J HOPPER; E JAWETZ; F HINMAN
Journal:  Am J Med Sci       Date:  1953-04       Impact factor: 2.378

3.  Renal medullary necrosis.

Authors:  E E MANDEL
Journal:  Am J Med       Date:  1952-09       Impact factor: 4.965

4.  An experimental basis of combined antibiotic action.

Authors:  E JAWETZ; J B GUNNISON
Journal:  J Am Med Assoc       Date:  1952-10-18

5.  Infections with Pseudomonas aeruginosa treated with polymyxin B.

Authors:  E JAWETZ
Journal:  AMA Arch Intern Med       Date:  1952-01

6.  Bacterial endocarditis.

Authors:  T H HUNTER
Journal:  Am Heart J       Date:  1951-09       Impact factor: 4.749

7.  LABORATORY AND CLINICAL STUDIES OF POLYMYXIN B AND E.

Authors:  E J Pulaski; H J Baker; M L Rosenberg; J F Connell
Journal:  J Clin Invest       Date:  1949-09       Impact factor: 14.808

8.  Medical aspects of pyelonephritis.

Authors:  R BIRCHALL; J E ALEXANDER
Journal:  Medicine (Baltimore)       Date:  1950-02       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.